Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$731.3m

Aura Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Natalie Holles

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Analysis Article • Nov 26

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 15

Aura Biosciences: Bringing Not-Quite-Viruses Closer To Fruition In Cancer

Summary Aura Biosciences has continued its long work on bel-sar in cancers of the eye, bringing to bear some very interesting signals. While they have sufficient funding for now, their own timelines to a phase 3 readout suggest they will face a cash crisis well in advance of topline, pivotal data. I am upgrading AURA stock to a "hold" sentiment based on a more favorable timeline, but not a buy due to severe risks of failure of their trials. Read the full article on Seeking Alpha
Analysis Article • May 03

Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 11

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 17

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Summary Aura Biosciences' lead asset, bel-sar, shows promising Phase 2 results for choroidal melanoma, with 80% tumor control and 90% vision preservation. Bel-sar's SPA designation by the FDA and its excellent safety profile position it favorably against current treatments like radiotherapy. Aura's financials are solid with a $499.53mn market cap and $187mn cash, providing a runway for its Phase 3 trial and additional studies. Despite minor cash risks, Aura's strong data, unmet medical need focus, and solid execution make it a compelling biotech investment. Read the full article on Seeking Alpha
Analysis Article • Sep 11

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Oct 03

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 28

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 01

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 19

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences (NASDAQ:AURA) is trading higher in the morning hours Tuesday after JMP Securities issued an Outperform rating as it started coverage on the clinical-stage biotech citing its novel therapeutic platform. The virus-like drug conjugates (VDC) platform Aura (AURA) is advancing “could establish a new standard of care in multiple cancer indications,” the analyst Jonathan Wolleben wrote with an DCF-derived price target of $26 per share for the stock. The firm highlights Aura’s (AURA) VDC candidate, AU-011, which is undergoing studies for choroidal melanoma, the commonest primary ocular cancer in adults, according to the analyst. In addition, JMP notes that Phase 2 data expected in the fall for AU-011 should de-risk the pivotal trial for the candidate scheduled to start later this year. In March, Aura (AURA) announced that the European Commission issued orphan drug designation for AU-011 as a treatment for several conditions of uveal melanoma, including choroidal melanoma.
Seeking Alpha • Jun 30

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

The U.S. Food and Drug Administration granted fast track designation to Aura Biosciences' (NASDAQ:AURA) belzupacap sarotalocan (AU-011) to treat non-muscle invasive bladder cancer. The company said AU-011 is its first virus-like drug conjugate product candidate, which it is developing for multiple oncology indications. "This milestone supports our goal to advance the development of belzupacap sarotalocan for patients with NMIBC in need of better and earlier targeted treatment options with the potential to help preserve the bladder," said Cadmus Rich, chief medical officer and head of R&D, Aura. The company said its phase 1 trial of AU-011 in this indication is expected to begin in H2 2022, with initial data expected in 2023. AURA +3.02% to $12.95 premarket June 30
Analysis Article • Apr 10

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO

Natalie Holles (53 yo)

less than a year
Tenure

Ms. Natalie C. Holles is Independent Director of LeonaBio, Inc. from May 5, 2026. Ms. Natalie C. Holles is President, CEO & Director of Aura Biosciences, Inc. from April 30, 2026. Ms. Holles served as Chie...

Leadership Team

NamePositionTenureCompensationOwnership
Anthony Gibney
Chief Financial & Business Officer1.1yrsUS$2.82m0.052%
$ 377.5k
Jill Hopkins
Chief Medical Officer & President of Research and Development2.7yrsUS$2.19m0.054%
$ 398.1k
Natalie Holles
Presidentless than a yearno datano data
Amy Elazzouzi
Interim Principal Accounting Officer1.8yrsno data0.11%
$ 796.0k
Mark Plavsic
Chief Technology Officer2.8yrsno data0.22%
$ 1.6m
Conor Kilroy
Chief Legal Officer & Secretary2.2yrsUS$2.13m0.036%
$ 262.8k
Patrick Nealon
Senior Vice President of Clinical Development Operations3.4yrsno datano data
Anthony Daniels
VP & Therapeutic Area of Head Ocular Oncology3.4yrsno datano data
Joe McQuaid
VP & Therapeutic Area Head of Urologic Oncologyless than a yearno datano data
2.2yrs
Average Tenure
54yo
Average Age

Experienced Management: AURA's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Natalie Holles
Presidentless than a yearno datano data
Evangelos Gragoudas
Scientific & Clinical Advisorno datano datano data
Sapna Srivastava
Independent Director5.1yrsUS$213.27k0.0095%
$ 69.6k
Jay Duker
Scientific & Clinical Advisorno datano datano data
Antony Mattessich
Independent Director4.8yrsUS$214.89k0.0095%
$ 69.6k
Giovanni Mariggi
Independent Director7.2yrsno datano data
Richard Carvajal
Scientific & Clinical Advisorno datano datano data
David Johnson
Independent Chairman of the Board5.4yrsUS$235.33k0.28%
$ 2.0m
Arun Singh
Scientific & Clinical Advisorno datano datano data
Carol Shields
Scientific & Clinical Advisorno datano datano data
Brian Marr
Scientific & Clinical Advisorno datano datano data
Karan Takhar
Independent Director5.3yrsno datano data
5.2yrs
Average Tenure
55yo
Average Age

Experienced Board: AURA's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 04:32
End of Day Share Price 2026/06/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan WollebenCitizens JMP Securities, LLC
Liisa BaykoEvercore ISI
Edward WhiteH.C. Wainwright & Co.